FIGURE 1 Given the role of GLP-1 in glycaemic control, the anti-apoptotic, growth-stimulating and insulin secretion-promoting effects on pancreatic -cells, the ability to re-sensitize the cellular insulin-signaling, minor side effects, good tolerance by normoglycemic patients and the fact that GLP-1 does not desensitize, synthetic GLP-1R agonists have been on the market for decades to treat type 2 diabetes mellitus (T2DM) or, more recently, to improve weight loss (Drucker, 2018)
Given its receptor selectivity profile, Ipamorelin is often included in research workflows exploring metabolic signaling, tissue remodeling processes, and physiological regulatory mechanisms related to growth hormone activity
Another benefit was that 20 percent of patients with type 2 diabetes who took liraglutide were able to reduce or discontinue their treatment with insulin (Holst 2024)
Tghe next generation are triple-agonists that combine GLP-1, GIP, and glucagon and they are already showing weight-loss results that rival those of bariatric surgery and metabolic improvements beyond what we see today
